Genomic evolution of *Bordetella pertussis* and post-COVID-19 resurgence of pertussis: insights from a global multi-country study

Haodong Zhang BSc[a,b, 1], Zhihua Kang M.D.[c,1], Yingying Zhang PhD[d,1],Yuanbin Yang BSc[e,1], Huiwen Li BSc[a,b], Naike Wang BSc [f], Jiancheng Wang BSc[f], Fuxiang Jiao BSc[f], Shanwei Tong BSc[f], Bingsong Wang M.S.[g], Song Gao PhD[h], Chengpei Ni PhD[h], Xiaolu Shi PhD[i], Shuang Wu PhD[i], Simo Huang M.D.[j], Danni Bao PhD[k], Qiushui He MD, PhD[l,m,n], Chuanqing Wang MD [a,b], Zhi Ruan PhD[d,o,p*], Pan Fu M.D.[a,b*], Chao Yang PhD[f,*]

[a.] Laboratory of Microbiology, Department of Clinical Laboratory, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[b.] Nosocomial Infection Control Department, Children's Hospital of Fudan University, National Children's Medical Center, Shanghai, China

[c.] Department of Laboratory Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, China.

[d.] Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.

[e.] Department of Microbiological Testing, Ningbo Municipal Center for Disease Control and Prevention, Ningbo, China

[f.] Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

[g.] Pediatric Respiratory Department, Wuhu No.1 People's Hospital, Wuhu, Anhui, China.

[h.] The Affiliated Wuxi Center for Disease Control and Prevention of Nanjing Medical University, Wuxi Center for Disease Control and Prevention, Wuxi, China

[i] Shenzhen Center for Disease Control and Prevention, Shenzhen, China;

[j.] Department of Clinical Laboratory, Seventh Medical Center, PLA General Hospital, Beijing, China;

[k.] Department of Clinical Laboratory, Sanmen People's Hospital, Taizhou, China;

[l.] Institute of Biomedicine, University of Turku, Turku, Finland;

[m.] InFLAMES Research Flagship Centre, University of Turku, Turku, Finland;

[n.] European Union (EU) Reference Laboratory for Diphtheria & Pertussis (EURL-PH-DIPE), Turku, Finland;

[o.] Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Hangzhou, China;

[p.] Zhejiang Provincial Engineering Research Center of Innovative Instruments for Precise Pathogen Detection, Hangzhou, China

[1] Those authors contribute equally

*Correspondence

Zhi Ruan, Email: r_z@zju.edu.cn

Pan Fu, Email: fup1028@163.com

Chao Yang, Email: cyang@siii.cas.cn

Summary

Background

A global resurgence of pertussis has occurred following the COVID-19 pandemic, yet the underlying drivers behind remain unclear. We aimed to investigate the role of *Bordetella pertussis* genomic evolution in the post-pandemic resurgence.

Methods

We integrated global purtussis surveillance data with 8117 genomic sequences of *B pertussis* isolated from 35 countries across six continents. Temporal dynamics in *B pertussis* genotypes, antigenic profiles and macrolide resistance before, during, and after the COVID-19 pandemic were analyzed.

Findings

Substantial post-pandemic shifts in *B pertussis* populations were observed in China and Australia. In China, the resurgence was driven by the rapid expansion of a single, recently emerged macrolide-resistant *B pertussis* (MRBP) clone, MR-MT28 (*ptxP3/fim3-1/prn150* or pertactin (PRN)-deficient), which replaced pre-existing strains. In Australia, MR-MT28 strains were introduced and expanded post-pandemic, with MRBP accounting for 23% (9/40) of sequenced genomes, along with a shift towards *ptxP3/fim3-2/prn2* genotypes and a decline in frequency of PRN-deficient strains. In Europe, a convergent post-pandemic rise in the *prn2* allele frequency together with significant decline in frequency of PRN-deficient strains was

observed. In addition, macrolide resistant strains (*ptxP3/fim3-1*/PRN-deficicent) emerged in 2024 in several European countries. Moreover, the MR-MT28 clone has been detected post-pandemic in four countries/continents (China, Australia, France, and the United States), with most isolates outside China (72%, 8/11) belonging to a PRN-deficient subclone.

Interpretation

The convergent and region-specific strain replacement and antigenic variation together with emergence of macrolide resistance post-pandemic suggest a key role for *B pertussis* adaptive evolution in the global pertussis resurgence. The emergence and international dissemination of the MR-MT28 strains represent a growing public health concern, highlighting the urgent need for coordinated global surveillance.

Funding

National Key Research and Development Program of China, National Natural Science Foundation of China, Youth Innovation Promotion Association, Chinese Academy of Sciences, Shanghai Rising-Star Program, Zhejiang Provincial Science and Technology Program for Disease Prevention and Control, Sigrid Juselius Foundation and Tampere Tuberculosis Foundation.

Key words: pertussis, *Bordetella pertussis*, resurgence, COVID-19, MR-MT28

Research in context

Evidence before this study

We searched PubMed for studies on the molecular epidemiology of pertussis resurgence following the COVID-19 pandemic using the terms ("*Bordetella pertussis*" OR "pertussis" OR "whooping cough") AND ("resurgence" OR "upsurge") for articles published between January 2022 and May 2025. A total of 92 relevant publications were identified. Among them, 33 studies described the resurgence of pertussis during or after the COVID-19 pandemic, but most focused on individual countries, including China, Finland, South Korea, and France. Only six studies used whole-genome sequencing to investigate the resurgence at the genomic

level, with four focusing on China, one on France, and one on Australia. However, no study has provided an integrated analysis of the dynamics of circulating *B pertussis* strains and the rising incidence of pertussis before, during, and after the pandemic at a global level. As a result, the relationship between *B pertussis* evolution and the recent global resurgence of pertussis remains poorly understood.

Added value of this study

This study represents the first global genomic investigation of *B pertussis* dynamics in the context of the global post-pandemic resurgence. We identified convergent and region-specific changes in *B pertussis* population and genetic variation associated with antibiotic resistance, vaccine escape, and virulence across continents. We demonstrate that in China, the resurgence was most likely driven by the expansion of a single macrolide-resistant clone (MR-MT28), while in Australia and several European countries, post-pandemic shifts in antigenic profiles (e.g., rise in *prn2*, decline in PRN-deficient strains) and emerging macrolide resistance were observed. Notably, we report post-pandemic international dissemination (identified across four continents) and ongoing evolution of the MR-MT28 clone by reconstructing its evolutionary dynamics and global spread patterns.

Implications of all the available evidence

Our findings suggest that adaptive evolution of *B pertussis* is a key contributor to the post-pandemic global resurgence of pertussis. The emergence and international spread of MR-MT28 strains raise additional concerns regarding potential treatment failures associated with resistant pertussis infections, and represent a growing public health concern, highlighting the urgent need for coordinated global surveillance.

Introduction

Pertussis, a highly contagious respiratory disease primarily caused by *Bordetella pertussis*, declined globally following the introduction of whole-cell and acellular vaccines.[1,2] Despite sustained high vaccination coverage, many countries have observed a resurgence over the past two decades, with a marked increase post-COVID-19 pandemic.[3–5]

121

122 According to the World Health Organization (WHO), following a sharp decline during the
123 COVID-19 pandemic (2020–2022), global pertussis cases rose substantially post-pandemic
124 (2023–2024), exceeding 800,000 notifications worldwide in 2024 —over at least four times
125 higher than the pre-pandemic average (**figure 1A**). In Asia, China and South Korea
126 reported >10-fold and >20-fold increases, respectively.[6–8] Several European countries,
127 including France, Czechia and Denmark, recorded historically high incidence.[9–12] Similar
128 surges were observed in Australia[13] and the United States[4] **(figure 1B)**.

129

130 Multiple factors underlie this resurgence, including immunity debt from pandemic-related
131 non-pharmaceutical interventions, waning vaccine-induced immunity, and adaptive evolution
132 of *Bordetella pertussis*.[2–7] Over recent decades, *B pertussis* has undergone notable genetic
133 shifts, including the emergence and prevalence of strains with *ptxP3* alleles potentially
134 associated with increased virulence,[14] and pertactin (PRN)-deficient variants, which may
135 evade vaccine-induced immunity.[15] In parallel, the emergence of macrolide-resistant *B*
136 *pertussis* (MRBP), particularly its predominance in China, has raised additional concern
137 regarding potential transmission and treatment failures.[16–19]

138

139 Of particular concern is the *ptxP3* MR-MT28 clone. It has been proposed as a major driver of
140 China's post-pandemic resurgence due to its combined features of vaccine escape and
141 antimicrobial resistance.[18,20] Notably, this clone has been recently detected in France[11,12] and
142 Australia,[13] raising concerns of international dissemination. Although the post-pandemic
143 resurgence of pertussis in China appears closely associated with the expansion of the MR-
144 MT28 clone, integrated analyses of dynamics of circulating *B pertussis* strains and rising
145 incidence of pertussis before, during and after the pandemic at global level have been not
146 performed.

147

148 In this study, we investigated the genomic evolution of *B pertussis* in the context of the global
149 post-pandemic resurgence. We found that lineage composition, vaccine antigen profiles, and
150 MRBP prevalence underwent substantial shifts in several regions in parallel with the rising

151 pertussis burden, providing evidence that adaptive evolution of *B pertussis* is one key
152 contributor to the recent global resurgence. Our analysis highlights that the MR-MT28 clone,
153 which drove the post-pandemic resurgence in China, has now spread to other three continents,
154 underscoring the urgent need for coordinated global surveillance.
155
156 **Methods**
157 **Pertussis case data**
158 Pertussis case numbers were obtained from the WHO website
159 (https://immunizationdata.who.int/global/wiise-detail-page/pertussis-reported-cases-and-
160 incidence). For countries or regions with incomplete WHO data, supplementary case counts
161 were searched and sourced from national public health agencies, including the US Centers for
162 Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and
163 Control (ECDC).
164
165 **Genome collection and sequencing**
166 We analysed a total of 8,368 non-redundant *B pertussis* genomes with unique Biosample
167 accession numbers, comprising 8112 publicly available genomes and 249 newly sequenced
168 isolates. Public genomes were retrieved from the NCBI Sequence Read Archive (SRA) and
169 GenBank, with isolation year and country extracted from BioSample metadata. Newly
170 sequenced isolates were collected from six regions in China: Shanghai (n=42), Zhejiang
171 (n=165), Anhui (n=7), Jiangsu (n=3), Sichuan (n=19), and Guangdong (n=13). Whole-
172 genome sequencing for newly sequenced isolates was performed on the Illumina NovaSeq
173 platform. Newly generated sequencing data are available in the NCBI SRA under accession
174 number PRJNA1288341.
175
176 Raw sequencing reads were quality-trimmed using Trimmomatic v0.39.[21] Genome assembly
177 was conducted using the shovill v1.1.0 pipeline (https://github.com/tseemann/shovill).
178 Assembly quality was assessed using CheckM v1.1.3.[22] Only high-quality genomes
179 (completeness >95%, contamination <5%) were retained in following analysis. Putative
180 mutator strains indicated by abnormal tree branches were also removed from analysis.

After genome quality control, a total of 8117 high-quality genomes (appendix p4, supplementary table 1) were used in the analysis, includes isolates collected between 1900 and 2024 from 35 countries across six continents: Europe (16 countries), Asia (6), North America (5), Africa (4), Oceania (2), and South America (2).

Phylogenetic and temporal analysis

Core-genome single nucleotide polymorphisms (SNPs) were identified using Snippy v4.6.0 (https://github.com/tseemann/snippy), based on raw reads or assemblies where reads were unavailable, with *B pertussis* Tohama I (NC_002929.2) as the reference. SNPs within repetitive regions were excluded as previously described.[23] Maximum-likelihood phylogenies were constructed using FastTree v2.1.10[24] (all strains) or RAxML-NG v1.0.1[25] with the GTR+Γ model (MR-MT28 clone).

Time-resolved phylogenies and effective population size dynamics were inferred using BEAST v1.10.4.[26] We applied GTR+Γ substitution model and used isolation date (years) for tip date calibration. Six combinations of molecular clocks (strict and uncorrelated relaxed clock) and coalescent tree models (constant size and Bayesian Skyline and Skygrid) were tested and Skygrid model were the best fit based on path sampling and steppingstone sampling analysis. We ran ten independent Markov chain Monte Carlo chains for 30 million steps, sampling every 3,000 steps. The results of different runs were combined to generate the maximum clade credibility trees using TreeAnnotator v1.10.4. Effective population size dynamics was inferred using Tracer v1.7.1.[27]

Vaccine antigen and macrolide resistance profiles

Vaccine antigen alleles were assigned by comparison with the curated *Bordetella* allele database on BIGSdb-Pasteur.[28] So far the only mechanism causing macrolide resistance has been the point mutation of A2047G in the 23S rRNA gene of *B pertussis*. Therefore, MRBP strains carrying the A2047G mutation were detected using BLASTn. Strains were classified as PRN-deficient if they carried incomplete or disrupted *prn* coding sequences or promoters

211 (BLASTn or TBLASTn coverage <99%), based on criteria defined by Lefrancq et al.[29]

212

213 **Role of the funding source**

214 The funders of the study had no role in study design, data collection, data analysis, data

215 interpretation, or writing of the report.

216

217 **Results**

218 **Global genomic diversity and population structure of *B pertussis***

219 We analysed 8,117 high-quality genomes, including 249 newly sequenced strains from six

220 regions in China. These genomes spanned 35 countries across six continents. Four continents

221 and five countries each had more than ten genomes from both pre-pandemic and during/post-

222 pandemic periods, enabling temporal and geographical comparisons (**figure 2A**; appendix p2,

223 supplementary figure 1).

224

225 A core-genome SNP-based phylogenetic tree was constructed to characterise the global

226 population structure of *B pertussis* (**figure 2B**). The phylogentic tree revealed that 99.6%

227 (8087/8117) of isolates belonged to lineage IIb,[30] which could be further divided into three

228 major sublineages based on *ptxP* and *fim3* genotypes: *ptxP1/fim3-1* (17%, n=1364),

229 *ptxP3/fim3-1* (60%, n=4812), and *ptxP3/fim3-2* (22%, n=1816). The difference between *fim3-*

230 *1* and *fim3-2* alleles is a point mutation of C260A causing an amino acid change (Ala87Glu),

231 and the difference between *ptxP1* and *ptxP3* is a point mutation of C to A in promoter of

232 pertussis toxin gene.

233

234 The MRBP-associated A2047G mutation in 23S rRNA gene were detected in 59% (811/1364)

235 of *ptxP1/fim3-1*, 11% (519/4812) of *ptxP3/fim3-1* and 0.3% (5/1817) of *ptxP3/fim3-2* strains.

236 Nearly all (99%, 513/519) *ptxP3/fim3-1* MRBP strains belonged to the MR-MT28 clone

237 (**figure 2B**), which was predominantly identified in China.[20]

238

239 **Lineage dynamics and variation in vaccine antigen and antibiotic resistance profiles**

240 Post-pandemic increases in pertussis were accompanied by convergent and region-specific

241 shifts in lineage composition, vaccine antigen profiles, and macrolide resistance (**figure 3,**
242 appendix p3, supplementary figure 2).
243
244 In Asia (n=2023), primarily represented by China (n=1645), the *ptxP3/fim3-1* sublineage
245 expanded rapidly during and after the pandemic, alongside a marked rise in MRBP frequency
246 and substantial shifts in antigen profiles (**figure 3**). This transition was driven by the
247 emergence and rapid expansion of the MR-MT28 clone. MR-MT28 (n=513) carried either
248 *ptxP3/fim3-1/prn150* (74%, 382/513) or *ptxP3/fim3*-1 with predicted PRN-deficiency (25%,
249 129/513) profiles, becoming the dominant clone (99%) post-pandemic in China (**figure 2B,**
250 **figure 3**). This clonal replacement also shifted the MRBP composition, from a pre-pandemic
251 predominance of *ptxP1/fim3-1* strains (87%, 774/891) to *ptxP3/fim3-1* (92%, 386/418) post-
252 pandemic (**figure 3B**). In line with the dominance of a single clone, the genetic diversity of
253 post-pandemic strains (median SNP distance: 8) was significantly decreased compared to that
254 of pre-pandemic strains (median SNP distance: 31; **figure 2C**).
255
256 Similarly, in Oceania (n=489), mainly represented by Australia (n=445), substantial post-
257 pandemic shifts were observed in sublineage distribution and antigen gene composition,
258 accompanied by an increase in MRBP prevalence (**figure 3**). Based on this genomic analysis,
259 MRBP prevalence notably reached 23% (9/40) post-pandemic—an unexpectedly high
260 frequency given the previous rarity of MRBP outside China,[19] and this rise was also
261 associated with the introduction of the MR-MT28 clone. Unlike Asia, changes in sublineage
262 and antigen gene profiles were largely driven by the rise of *ptxP3/fim3-2* sublineage and *fim3-*
263 *2* and *prn2* alleles, along with a decreased frequency of predicted PRN-deficient strains
264 (**figure 3**).
265
266 Post-pandemic strains in Oceania remained genetically diverse, with *ptxP3/fim3-2* and
267 *ptxP3/fim3-1* sublineages present at 45% (18/40) and 53% (21/40), respectively. Accordingly,
268 genetic diversity remained relatively stable post-pandemic. Phylogenetic analysis showed that
269 close relatives of most post-pandemic strains were already circulating before the pandemic,
270 with the exception of MR-MT28, suggesting that the resurgence in Oceania might be driven

271 by the expansion of locally pre-existing lineages (**figures 2B, figure 3**).

272

273 In Europe (n=2595), mainly represented by France (n=1308) and Belgium (n=429), noticeable
274 post-pandemic changes were observed in the vaccine antigen gene *prn*. As in Australia, the
275 frequency of the *prn2* allele increased post-pandemic, while the frequency of predicted PRN-
276 deficient strains decreased (**figure 3**). One MR-MT28 strain was detected in France in 2024.

277

278 Overall genetic diversity in Europe did not significantly decline post-pandemic, although two
279 dominant clones (Europe clone 1 and 2, accounting for 65% of post-pandemic strains) were
280 identified (**figure 2B**). Both clones were already present pre-pandemic, indicating continued
281 transmission of locally endemic strains. However, this varied by country—for instance, post-
282 pandemic strains in Belgium showed significantly reduced diversity, with 70% (64/91)
283 belonging to Europe clone 2 (**figure 2B,C**).

284

285 In North America (n=2,832), primarily represented by the United States (n=2,798), strain
286 dynamics remained relatively stable. The North America clone 1, prevalent pre-pandemic,
287 remained dominant post-pandemic (67%, 69/103), continuing to drive endemic circulation
288 (**figure 2B**). One MR-MT28 strain was identified in the United States in 2024.

289

290 **Evolutionary dynamics and global spread of the MR-MT28 clone**

291 The MR-MT28 clone was detected in four countries (China, Australia, France, and the United
292 States) across four continents post-pandemic (**figure 4A, B**), indicating its potential for global
293 dissemination. We therefore investigated its evolutionary origin and patterns of international
294 spread.

295

296 Phylogenetic analysis suggested that MR-MT28 evolved from the MS-MT28 lineage, which
297 was primarily identified in Europe and North America pre-pandemic (**figure 4C, D**).
298 Although MR-MT28 has become dominant in eastern China post-pandemic, it remains at
299 relatively low frequency in western regions (**figure 4B**). Molecular clock analysis estimated
300 the emergence of MR-MT28 around 2016 (95% CI: 2014–2018), most likely originating in

China, where it now predominates. Consistent with the observed rise in MR-MT28 cases and its geographic expansion, its effective population size increased sharply post-pandemic—more than 1,000-fold in 2024 compared to 2021 (**figure 4E**).

Compared to its ancestor MS-MT28, the MR-MT28 clone harbours two defining mutations: the macrolide resistance-associated A2047G mutation in the 23S rRNA gene, and a synonymous G1959A mutation in *BP0685* (dehydrogenase/oxidase). The novel antigen allele *prn150*, found predominantly in MR-MT28, was also present in one MS-MT28 strain from Shanghai, China.

Two emerging subclones were identified within MR-MT28 (**figure 4C, D**). Subclone 1 (SC1), estimated to have emerged around 2019, is characterised by predicted PRN deficiency, a nonsynonymous mutation in *BP3197* (G287T; Arg96Leu; NAD(P)-dependent oxidoreductase), and, in a subset of strains, a mutation in *BP0026* (G370T; Ala124Ser; thiolase family protein). Notably, most (7/9) MR-MT28 strains detected in Australia and the single French isolate belonged to SC1, suggesting enhanced transmission potential, possibly associated with immune evasion.

Subclone 2 (SC2) harboured three distinct mutations: *BP2642A* (C664T; Pro222Ser; ABC transporter ATP-binding protein), *BP3467* (G1621A; Asp541Asn; AsmA family protein), and a synonymous mutation in *BP3491* (C318A; NAD(P)/FAD-dependent oxidoreductase). Intrigulingly, both subclones independently accumulated mutations in NAD(P)-dependent oxidoreductase genes (*BP3197* in SC1 and *BP3491* in SC2), suggesting convergent adaptation.

Discussion

The global resurgence of pertussis appears to be multifactorial, shaped by both host-related and pathogen-related drivers.[2–7] Although the impact of host-relalted factors, such as non-pharmaceutical interventions and waning immunity, are difficult to quantify, genomic surveillance enables comprehensive characterisation of pathogen evolution. In this study, we

systemically analyzed all available sequences of *B pertussis* strains in the world and compared the results with incidences of pertussis before, during and after the COVID-19 pandemic. Our findings reveal substantial or noticeable post-pandemic shifts in *B pertussis* lineage composition, vaccine antigen profiles, and macrolide resistance across three continents, with the most pronounced changes observed in China and Oceania.

In particular, we observed the rise of genotypes carrying mutations associated with antibiotic resistance, vaccine escape (PRN-deficient strains), and potential increases in virulence (e.g., *ptxP3* strains). The clearest evidence of such adaptive evolution was observed in China, where the *ptxP3* MR-MT28 clone, encoding a novel *prn150* allele, emerged as the dominant post-pandemic clone. This clone, capable of causing infections among older children and vaccinated individuals, was most likely the primary driver of the post-pandemic pertussis upsurge in China.[18,20]

Patterns of strain replacement and antigenic variation exhibited both convergent and divergent trends across continents. First, increased MRBP prevalence and higher frequencies of the *ptxP3* and *prn150* alleles were observed in both China and Australia post-pandemic, largely driven by the expansion of the MR-MT28 clone. Second, PRN-deficient strains declined in prevalence in Europe, Australia, and the United States after the pandemic, accompanied by a concurrent rise in the *prn2* allele.[31] Third, the *fim3-1* allele, already predominant before the pandemic, further increased in frequency in China, Europe, and the United States post-pandemic.

Region-specific trends revealed distinct adaptive trajectories. In China, the post-pandemic resurgence was driven by the clonal expansion of MR-MT28, in contrast to the polyphyletic strain composition observed in other regions. Notably, the prevalence of PRN-deficient strains uniquely increased in China post-pandemic, despite being rarely reported pre-pandemic and declining in frequency in many other countries.[11,32,33] This suggests that PRN deficiency may confer context- and time-dependent advantages, potentially shaped by regional vaccine formulations, the duration of vaccine use, and extent of exposure to pertussis in the

361 population. In Australia, the frequency of the *fim3-2* allele uniquely rose post-pandemic. This
362 allele had shown a global increase beginning in 1996, coinciding with the transition from
363 whole-cell to acellular vaccines.[30] However, its global frequency has gradually declined since
364 2020 for reasons that remain unclear. The *fim3-2* allele has also been reported to be associated
365 with enhanced biofilm formation[34]. Together, these findings may reflect region-specific
366 selective pressures and potential local adaptation in China and Australia.
367
368 Despite the long-standing predominance of *ptxP1* MRBP strains in China for over a decade,
369 they remain rarely detected elsewhere.[16–19] In contrast, *ptxP3* MR-MT28 clone has been
370 identified across four continents, suggesting that it may possess distinctive features
371 facilitating international spread. Indeed, the *ptxP3* strains appeared in Australia, Europe and
372 the USA in 1990s and became prevalent since then. Our genomic analysis revealed a notable
373 post-pandemic rise in MRBP prevalence in Australia, reaching 23% post-pandemic. This was
374 further supported by targeted culture-independent sequencing screening, which estimated
375 MRBP prevalence of 4.4%.[13] In addition to the MR-MT28 strain identified in this study from
376 France, a recent French study showed that overall MRBP accounted for 2.8% (17/593) of the
377 tests (culture and qPCR) in 2024. Phylogenetic analysis revealed that the 14 MRBP belong,
378 together with isolates from China, to a cluster of 349 MRBP isolates. All 14 MRBP carried
379 *ptxP3*, and 13 of them were PRN-deficient.[11,12] MRBP strains have recently been identified in
380 other European countries such as Finland.[33] Thus, the geographic range of MR-MT28
381 described here only represents a minimum estimate.
382
383 Most MR-MT28 strains detected in Australia and France were PRN-deficient, suggesting that
384 PRN deficiency may confer additional advantages, such as enhanced vaccine escape potential.
385 Together, these findings indicate that MR-MT28 represents a significant risk for global
386 dissemination and underscore the urgent need for strengthened international surveillance,
387 particularly targeting PRN-deficient MR-MT28 strains.
388
389 This study has several limitations. First, the publicly available genomic data used for
390 contextualisation are subject to inherent sampling biases. Since the number of genomes

available across countries and continents varies substantially, the results should be interpreted with caution. Second, recent genomic data from several regions, particularly the United States and parts of Europe, are limited or unavailable for comparison. Third, the number of isolates during the pandemic is very limited, which may affect our understanding of circulating strains during that period. Finally, vaccination programmes, vaccine types used, and non-pharmaceutical interventions varied across countries, and the resulting selection pressures in different populations may differ accordingly.

In conclusion, our study provides genomic evidence that the adaptive evolution of *B pertussis*, through lineage replacement, antigenic variation, and antimicrobial resistance, has played a significant role in the post-pandemic resurgence of pertussis. The emergence and international dissemination of the MR-MT28 clone represent a growing public health challenge, emphasising the need for coordinated global surveillance and updated vaccine strategies.

Contributors

P.F. and Y.C. contributed to the conception of this project. Z.R., Y.Z., P.F., Z.K., Y.Y. B.W., D.B., S.G., C.N., X.S., S.W., S.H. were responsible for collection of strains and metadata. H.Z., C.Y., H.L., N.W., J.W., F.J., S.T. performed bioinformatics analysis of whole genome sequence data. Y.C., P.F. and Q.H. prepared the manuscript. All authors contributed to the interpretation of results and critical review of the manuscript.

Declaration of interests

We declare no competing interests.

Data sharing

Accession numbers for the publicly available genome sequences and associated metadata can be found in appendix and Zenodo (DOI:10.5281/zenodo.15900428). Newly sequenced genomes in this study are available from the National Centre for Biotechnology Information database under BioProject PRJNA1288341.

Acknowledgments

This work was supported by grants from National Key Research and Development Program of China (2022YFC2304700), National Natural Science Foundation of China (82202567, 32270003), Youth Innovation Promotion Association, Chinese Academy of Sciences (2022278), and Shanghai Rising-Star Program (23QA1410500), Zhejiang Provincial Science and Technology Program for Disease Prevention and Control (2025JK139), Sigrid Juselius Foundation (240045) and Tampere Tuberculosis Foundation (26006205).

Reference

1 Kapil P, Merkel TJ. Pertussis vaccines and protective immunity. Curr Opin Immunol. 2019; **59**: 72–8.

2 Domenech de Cellès M, Rohani P. Pertussis vaccines, epidemiology and evolution. *Nat Rev Microbiol* 2024; **22**: 722–35.

3 Locht C. Pertussis before, during and after Covid-19. *EMBO Mol Med* 2025; **17**: 594-598–598.

4 Kang HM, Lee T-J, Park SE, Choi S-H. Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management. *Infect Chemother* 2025; **57**: 13–30.

5 Bricks LF, Vargas-Zambrano JC, Macina D. Epidemiology of Pertussis After the COVID-19 Pandemic: Analysis of the Factors Involved in the Resurgence of the Disease in High-, Middle-, and Low-Income Countries. *Vaccines* 2024; **12**.

6 Liu Y, Yu D, Wang K, Ye Q. Global resurgence of pertussis: A perspective from China. *Journal of Infection* 2024; **89**.

7 Mengyang G, Yahong H, Qinghong M, Wei S, Kaihu Y. Resurgence and atypical patterns of pertussis in China. *Journal of Infection* 2024; **88**.

8 Lee H, Cho UJ, Kim A-R, *et al.* Resurgence of Pertussis in the Gyeongnam Region of South Korea in 2023 and 2024. *Vaccines* 2024; **12**.

9 Nordholm AC, Emborg H-D, Nørgaard SK, *et al.* Pertussis epidemic in Denmark, August 2023 to February 2024. *Eurosurveillance* 2024; **29**: 2400160.

10 Monchausse T, Launay T, Rossignol L, *et al.* Clinical characteristics of cases during the 2024 pertussis epidemic in France, January 2024 to December 2024. *Vaccine* 2025; **51**: 126862.

452 11 Rodrigues C, Bouchez V, Soares A, *et al.* Resurgence of Bordetella pertussis, including
453 one macrolide-resistant isolate, France, 2024. *Eurosurveillance* 2024; **29**: 2400459.

454 12 Bouchez V, Lefrancq N, Toubiana J, Rodrigues C, Brisse S. Microbes know no
455 borders: importation of macrolide-resistant Bordetella pertussis into France in 2024.
456 *Clinical Microbiology and Infection* 2025; published online July 13.

457 13 Fong W, Rockett RJ, Tam KK-G, *et al.* Targeted Culture-Independent Sequencing
458 Identifies Emergence of Macrolide-Resistant Bordetella Pertussis in Australia.
459 *medRxiv* 2024.

460 14 Mooi FR, Van Loo IHM, Van Gent M, *et al.* Bordetella pertussis strains with increased
461 toxin production associated with pertussis resurgence. *Emerg Infect Dis* 2009; **15**.

462 15 Ma L, Caulfield A, Dewan KK, Harvill ET. Pertactin-deficient Bordetella pertussis,
463 vaccine-driven evolution, and reemergence of pertussis. *Emerg Infect Dis* 2021; **27**.

464 16 Wu X, Du Q, Li D, *et al.* A Cross-Sectional Study Revealing the Emergence of
465 Erythromycin-Resistant Bordetella pertussis Carrying ptxP3 Alleles in China. *Front*
466 *Microbiol* 2022; **13**.

467 17 Fu P, Zhou J, Meng J, *et al.* Emergence and spread of MT28 ptxP3 allele macrolide-
468 resistant Bordetella pertussis from 2021 to 2022 in China. *International Journal of*
469 *Infectious Diseases* 2023; **128**: 205–11.

470 18 Fu P, Zhou J, Yang C, *et al.* Molecular Evolution and Increasing Macrolide Resistance
471 of Bordetella pertussis, Shanghai, China, 2016–2022. *Emerg Infect Dis* 2024; **30**: 29.

472 19 Feng Y, Chiu C-H, Heininger U, *et al.* Emerging macrolide resistance in Bordetella
473 pertussis in mainland China: Findings and warning from the global pertussis initiative.
474 *The Lancet Regional Health-Western Pacific* 2021; **8**: 98.

475 20 Fu P, Yan G, Li Y, *et al.* Pertussis upsurge, age shift and vaccine escape post-COVID-
476 19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China.
477 *Clinical Microbiology and Infection* 2024; **30**: 1439–46.

478 21 Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina
479 sequence data. *Bioinformatics* 2014; **30**: 2114–20.

480 22 Parks DH, Imelfort M, Skennerton CT, Hugenholtz P, Tyson GW. CheckM: Assessing
481 the quality of microbial genomes recovered from isolates, single cells, and
482 metagenomes. *Genome Res* 2015; **25**: 1043–55.

483 23 Yang C, Li Y, Jiang M, *et al.* Outbreak dynamics of foodborne pathogen Vibrio
484 parahaemolyticus over a seventeen year period implies hidden reservoirs. *Nat*

485 *Microbiol* 2022; **7**: 1221–9.

486 24 Price MN, Dehal PS, Arkin AP. FastTree 2 – Approximately Maximum-Likelihood
487 Trees for Large Alignments. *PLoS One* 2010; **5**: e9490.

488 25 Kozlov AM, Darriba D, Flouri T, Morel B, Stamatakis A, Wren J. RAxML-NG: A fast,
489 scalable and user-friendly tool for maximum likelihood phylogenetic inference.
490 *Bioinformatics* 2019.

491 26 Drummond AJ, Rambaut A. BEAST: Bayesian evolutionary analysis by sampling
492 trees. *BMC Evol Biol* 2007; **7**.

493 27 Rambaut A, Drummond AJ, Xie D, Baele G, Suchard MA. Posterior summarization in
494 Bayesian phylogenetics using Tracer 1.7. *Syst Biol* 2018; **67**.

495 28 Bridel S, Bouchez V, Brancotte B, *et al.* A comprehensive resource for Bordetella
496 genomic epidemiology and biodiversity studies. *Nat Commun* 2022; **13**.

497 29 Lefrancq N, Bouchez V, Fernandes N, *et al.* Global spatial dynamics and vaccine-
498 induced fitness changes of *Bordetella pertussis*. *Sci Transl Med* 2022; **14**: 3253.

499 30 Bart MJ, Harris SR, Advani A, *et al.* Global population structure and evolution of
500 Bordetella pertussis and their relationship with vaccination. *mBio* 2014; **5**.

501 31 Barkoff AM, Mertsola J, Pierard D, *et al.* Surveillance of circulating bordetella
502 pertussis strains in Europe during 1998 to 2015. *J Clin Microbiol* 2018; **56**.

503 32 Kastrin T, Barkoff A-M, Seme K, *et al.* Pertussis epidemic in Slovenia in 2024: no
504 pertactin-deficient or macrolide-resistant Bordetella pertussis isolates identified.
505 *Clinical Microbiology and Infection* 2025.

506 33 Miettinen M, Barkoff AM, Nyqvist A, *et al.* Macrolide-resistant Bordetella pertussis
507 strain identified during an ongoing epidemic, Finland, January to October 2024.
508 *Eurosurveillance* 2024; **29**.

509 34 Niinikoski V, Barkoff AM, Mertsola J, He Q. Bordetella pertussis isolates in Finland
510 after acellular vaccination: serotype change and biofilm formation. *Clinical*
511 *Microbiology and Infection* 2024; **30**..

512

513

514 **Figure legends**

515 **Figure 1. Global pertussis case numbers and incidence rates since 2000.** (A) Trends in
516 pertussis case numbers and incidence rates for the world and four continents. (B) Trends for
517 four countries with more than ten *B pertussis* genomes from pre-, during-, and post-pandemic
518 periods. Incidence rates are shown per 100 000 population.

519

520 **Figure 2. Global population structure and resistance and antigenic profiles of *B***
521 ***pertussis*.** (A) Annual number of high-quality genomes from four continents. (B) Maximum-
522 likelihood phylogenetic tree of global isolates, annotated with geographic location and
523 macrolide resistance and vaccine antigen profiles. (C) Pairwise core-genome SNP distance
524 distributions within and between time periods (pre-, during-, and post-pandemic) for each
525 continent and representative countries.

526

527 **Figure 3. Temporal dynamics of *B pertussis* lineages (A), macrolide resistance (B), and**
528 **antigenic (C) profiles.** Background colours indicate different time periods (pre-, during-, and
529 post-pandemic). Lines show the proportion of strains; point sizes indicate the number of
530 genomes; line and point colours represent each continent or country.

531

532 **Figure 4. Evolutionary dynamics and global dissemination of the MR-MT28 clone.** (A,
533 B) Geographic distribution of MR-MT28 strains post-pandemic (2023–2024), globally and
534 within China. Pie charts indicate the regional proportion of MR-MT28. (C) Maximum-
535 likelihood phylogeny of the MT28 clone. Tip colours represent country of origin. Outer rings
536 denote macrolide resistance (MR or MS) and *prn* allele profiles. (D) Time-calibrated
537 phylogeny of the MT28 clone with resistance status and *prn* allele profiles. Key time points,
538 genetic events, and 95% confidence intervals are indicated by arrows, triangles, and shaded
539 orange rectangles, respectively. (E) Temporal changes in the effective population size of the
540 MT28 clone inferred using Bayesian Skygrid analysis.


A
Pre-pandemic
During-pandemic
Post-pandemic
Incidence
Cases
North America
Asia
Europe
Oceania
Global
Case numbers (×1000)
Incidence rate (per 100000 population)
Year
B
China
France
Belgium
Australia
United States
Incidence
Cases
Case numbers (×1000)
Incidence rate (per 100000 population)
Year


A
Asia
Oceania
Europe
North America
Count
1000
500
0
2000
2012
2024
B
0.01
lineage II
IIb
IIa
lineage I
0.001
ptxP3/fim3-2
ptxP3/fim3-1
ptxP1/fim3-1
North America clone 1
Europe clone 1
MR-MT28
Europe clone 2
Asia
Oceania
Europe
North America
Resistance
Vaccine antigen gene
ptx
fim
ptxP
ptxA
ptxB
ptxC
ptxD
ptxE
fim2
fim3
fhaB
prn
Periods
Pre-pandemic
During-pandemic
Post-pandemic
Resistance
MR
MS
Antigen gene sequence typing
1
2
3
4
150
Others
Predicted PRN-deficient
C
Asia
Oceania
Europe
North America
Pre−pandemic
Post−pandemic
Pre- vs. Post -pandemic
0
50
100
China
Australia
France
Belgium
United States
Pairwise SNP Distance


Continent
Country
A
B
C
Proportion
ptxP1/fim3-1
ptxP3/fim3-1
ptxP3/fim3-2
MR
ptxP1-MR
ptxP3-MR
fim3-1
fim3-2
ptxP3
prn2
prn150
Predicted PRN-deficient
Asia
Oceania
Europe
China
Australia
Belgium
France
Continent Asia Oceania Europe North America
Country China Australia France Belgium United States
Time-span Pre-pandemic During-pandemic Post-pandemic
Sample size 10–30 30–100 >100


A
MR−MT28
Others
United States, 1/170
France, 1/82
China, 499/615
Australia, 9/41
B
Beijing, 3/3
Hebei, 0/1
Anhui Wuhu, 7/7
Jiangsu Wuxi, 3/3
Shanghai, 236/282
Zhejiang Jiaxing, 12/13
Zhejiang Ningbo, 142/143
Zhejiang Taizhou, 21/22
Zhejiang Yiwu, 33/63
Chengdu, 1/19
Guangdong, 41/59
C
MR-MT28
MS-MT28
Australia
USA
France
SC1
SC2
Continent
Americas
Asia
Europe
Oceania
Resistance
MR
MS
PRN
prn2
prn150
prn-others
Predicted PRN-deficient
D
Resistence
PRN
SC2
BP2642A (C664T),
BP3467 (G1621A),
BP3491 (C318A)
SC1
prn-, BP3197 (G370T)
2016
(2014-2018)
MR-MT28
23S rRNA (A2047G)
BP0685 (G1959A), prn150
2005
2010
2015
2020
2025
E
Effective population size
10⁶
10⁵
10⁴
10³
10²
10
1
0.1
2010
2015
2020